13 May 2020 - NICE has recommended NHS funding for a cancer drug, giving final guidance on a new option for certain patients with follicular lymphoma.

For follicular lymphoma NICE has recommended Roche’s Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy.

Follicular lymphoma is the most common type of non-Hodgkin’s lymphoma, for which there is currently no cure.

Read Pharmaphorum article